VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

ISH 2022 | Inotuzumab ozogamicin and blinatumomab prior to and after alloHSCT in R/R Ph+ ALL

Naoki Hosen, PhD, Osaka University Graduate School of Medicine, Osaka, Japan, comments on the use of inotuzumab ozogamicin and blinatumomab prior to and after allogeneic hematopoietic stem cell transplantation (alloHSCT) in patients with relapsed/refractory (R/R) Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL). This interview took place at the 38th World Congress of the International Society of Hematology 2022.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter